Question: What year was the pharmaceutical company that markets Mylotarg purchased by Pfizer?

<P0-S0>  The company was founded in Philadelphia, Pennsylvania, in 1860 as John Wyeth and Brother. <P0-S1> Wyeth was a pharmaceutical company purchased by Pfizer in 2009. <P0-S2>  It was later known as American Home Products before being renamed to Wyeth in 2002. <P0-S3>  Its headquarters moved to Collegeville, Pennsylvania, and Madison, New Jersey, before its headquarters were consolidated with Pfizer's in New York City after the 2009 merger. <P0-S4>  The infant and maternal nutrition business was acquired by Nestlé in 2012. <SEP> <P1-S0> Peter Rost, M.D. is a former drug marketing executive and is most known for taking public stances critical of the pharmaceutical industry as an "insider" and whistleblower. <P1-S1>  He sued his last two pharmaceutical employers, Wyeth and Pfizer, the latter of which fired him in 2005. <P1-S2>  At Wyeth, he uncovered tax evasion practices, and after informing senior company executives, was transferred from Sweden to a post in New Jersey. <P1-S3>  Rost sued the company, saying that the transfer was a retaliatory demotion, though the company said it was a promotion. <P1-S4>  Rost settled with Wyeth for an undisclosed amount in 2003. <P1-S5>  At Pfizer, Rost filed a "qui tam" suit disclosing off-label marketing of Genotropin at Pharmacia prior to its purchase by Pfizer. <P1-S6>  The U.S. Department of Justice declined to join in Rost's suit as the marketing violations had already been disclosed to the Department by Pfizer. <P1-S7>  Rost was eventually fired by Pfizer, and sued for wrongful dismissal, but this lawsuit was summarily dismissed by the court based on evidence that Pfizer had decided to fire Rost prior to discovery of his whistleblowing activities. <P1-S8>  Since then, Rost has worked outside the pharmaceutical industry, as a public speaker, blogger, writer, and litigation consultant. <SEP> <P2-S0> Ethchlorvynol is a GABA-ergic sedative and hypnotic/soporific medication developed by Pfizer in the 1950s. <P2-S1>  In the United States it was sold by Abbott Laboratories under the tradename Placidyl. <P2-S2>  Placidyl was available in 200 mg., 500 mg., and 750 mg. <P2-S3>  strength capsules. <P2-S4>  While the 500 mg. <P2-S5>  and 750 mg. <P2-S6>  strength capsules were for use in reducing sleep latency, the 200 mg. <P2-S7>  strength capsules were intended to be used to re-induce sleep in case of early awakening. <P2-S8>  Abbott discontinued production in 1999, after which Placidyl was available for about a year in the United States. <P2-S9>  Although, theoretically, ethchlorvynol could be manufactured for sale in the United States by another pharmaceutical company (subject to FDA approval of such manufacture), no pharmaceutical company has chosen to do so. <P2-S10>  Individuals with a valid prescription for the substance may legally transport a reasonable amount of ethclorvynol with them into the United States. <SEP> <P3-S0> Gemtuzumab ozogamicin (marketed by Wyeth as Mylotarg) is a drug-linked monoclonal antibody (an antibody-drug conjugate) that was used to treat acute myeloid leukemia from 2000 to 2010. <P3-S1>  It was withdrawn from market in June 2010 when a clinical trial showed the drug increased patient death and added no benefit over conventional cancer therapies. <P3-S2>  It was re-introduced into the US market in 2017.